 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 4 | 1/1 | 返回列表 |
| 查看: 915 | 回復: 3 | |||
古可ぷ榮譽版主 (文壇精英)
|
[交流]
轉：具有全新降低血糖機制的新藥被fda專家小組否定 已有2人參與
|
|
轉自丁香園http://xdrug.dxy.cn/bbs/thread/20653328?keywords=»具有全新降低血糖機制的新藥被fda專家小組否定#20653328 作者：blueskychina FDA Panel Votes Against Diabetes Pill，Matthew Perrone，Drug Discovery & Development - July 20, 2011 fda15人專家小組昨天9對6票否定治療糖尿病新藥的決定，其理由是對此藥可能引發(fā)癌癥的數(shù)據(jù)不足。這不是fda官方最后決定，但是可以看成是官方?jīng)Q定。 此藥具有全新機制的控制血糖功能，通過清除尿中葡萄糖量而降低血中糖量，此作用機理和傳統(tǒng)降血糖機理完全不一樣， 是一類全新降糖藥物，也是這類作用機理中第一個藥物。 由于是全新機制的降血糖藥物，審評者對這些數(shù)據(jù)的評估也沒有很多經(jīng)驗，有一個參入評審者說在要在做出最后決定之前的10秒鐘他的主意改變了4次，當然這是和夸張的說法，但是可以看出對新機制藥物要做出正確的決定很艱難，哪怕你有很多可靠的數(shù)據(jù)。 此藥的有效性方面沒有多少疑問。主要關注在是否引發(fā)癌癥、肝臟毒性和感染方面，數(shù)據(jù)顯示和對照組比較很難讓人放心，例如在超過5000個病人中用藥組膀胱癌發(fā)現(xiàn)有9例而非用藥組沒有一個，這樣的數(shù)據(jù)很明顯表面膀胱癌發(fā)病率和用藥的關系，特別是在這么大的樣本中。 本人的看法是此藥如果再做癌癥安全方面的實驗，很難通過，因為現(xiàn)有的數(shù)據(jù)已經(jīng)比較清楚說明了膀胱癌和藥物的關系。個再做同樣實驗，結果很難被推翻。 從這樣的臨床實驗看，具有全新機制的藥物研發(fā)風險很大，而且不可控。嚴重不良反應真的很難預測和控制。但是這樣的實驗給后來者奠定了很好的基礎，也許會少犯同樣的錯誤。 其實在任何一個臨床試驗數(shù)據(jù)里都可以找到很多問題，只要不是核心的就好。在這個實驗中，有人說老年人和非美籍病例數(shù)太少。如果有了這些數(shù)據(jù)，一定有人會說亞裔病人太少。問題是在一個臨床試驗中不可能包涵所有情況。 大家猜猜公司還會繼續(xù)補充安全性方面的數(shù)據(jù)��？我想會的，理由是這2個公司都很有實力，錢不是最大問題，對于這樣全新機制的新藥有效性沒有問題，現(xiàn)在放棄很可惜。 下面是全文： WASHINGTON (AP) - The majority of advisers on a federal health panel say a first-of-a-kind diabetes drug that uses a new method to reduce blood sugar shouldn't be approved for U.S. patients after higher rates of bladder and breast cancer were reported among patients in company trials.A Food and Drug Administration panel voted 9-6 against the experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca, while expressing hope that the drug might ultimately be approved if safety questions are resolved. The vote is only a recommendation for FDA, which will make a final decision on the drug before the end of October. Dapagliflozin is a once-a-day pill designed to help diabetics eliminate excess sugar in their urine. That differs from older drugs that decrease the amount of sugar absorbed from food and stored in the liver. The companies have touted it as the first in a new class of drugs to address the nation's growing diabetes epidemic, which affects more than 25 million people. Nearly all the panelists praised the drug's innovative approach to lowering blood glucose, but a majority said they wanted more information on a host of safety concerns, including cancer, infections and possible liver toxicity. "It was the closest of calls, I changed my mind about four times in the last 10 seconds," said Dr. Erica Brittain, a biostatistician with the National Institutes of Health, who voted against the drug. "The level of evidence about the cancer is fairly weak, but it's just that the uncertainty is still there." The companies reported nine bladder cancers among over 5,000 people taking the drug in company studies, compared with none among those taking a dummy pill. There were nine cases of breast cancer among 2,100 women taking the drug, compared with one in the control group. While the company studies were not designed to measure cancer risk, panelists noted that the incidence of cancers was four to five times higher than expected in the population. Panelists said they would like more data on cancer rates in patients, but acknowledged that a definitive study of the risk probably would not be feasible, since it would mean enrolling more than 30,000 patients for several years. "There are some things we can't learn from clinical trials," said Dr. Ed Hendricks of the Center for Weight Management in Sacramento, Calif., who voted to approve the drug. "Sometimes to introduce new, innovative medical therapies we have to make decisions with a certain amount of uncertainty." The drug was also associated with bladder and urinary tract infections, due to increased sugar eliminated in patients' urine, and the companies suggested this factor may have led to higher detection of bladder cancers. That rationale did not explain why bladder cancers reported were limited to men, since urinary tract infections are more common in women. Panelists also complained about the small number of elderly and African-American patients enrolled in company studies. People in those groups are more predisposed to have diabetes. People with type 2 diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or have become resistant to the hormone, which controls blood sugar levels. These patients are at higher risk for heart attacks, kidney problems, blindness and other serious complications. Diabetics often require multiple drugs with different mechanisms of action to control their blood sugar levels. New York-based Bristol-Myers Squibb Co. and London-based AstraZeneca PLC already co-market the diabetes drug Onglyza, which increases insulin production while reducing glucose production. Date: July 19, 2011 Source: Associated Press [ Last edited by 古可ぷ on 2011-9-29 at 22:49 ] |
回復此樓» 猜你喜歡
酰胺縮合
已經(jīng)有3人回復
-
藥學專碩調(diào)劑
已經(jīng)有2人回復
-
藥理學論文潤色/翻譯怎么收費?
已經(jīng)有95人回復
-
藥學學碩326求調(diào)劑
已經(jīng)有1人回復
-
105500藥學調(diào)劑，一志愿頂9，主持省級大創(chuàng)，實驗型SCI二作，四六級已過，雙國獎
已經(jīng)有6人回復
-
藥學專碩調(diào)劑
已經(jīng)有0人回復
-
publcif的使用
已經(jīng)有0人回復
-
求調(diào)劑
已經(jīng)有2人回復
-
會計專碩求調(diào)劑
已經(jīng)有0人回復
-
藥學專碩申博
已經(jīng)有1人回復
-
新加坡國立大學藥學系化學生物學課題組招PhD
已經(jīng)有6人回復
» 本主題相關價值貼推薦，對您同樣有幫助:
- 哪位大俠幫忙翻譯一下 一篇FDA的 資料 共10頁（字不多）
已經(jīng)有3人回復
- 2012年3月FDA批準新藥
已經(jīng)有8人回復
- FDA/歐盟/日本 08-12年全球批準新藥匯總報告
已經(jīng)有94人回復
- 非諾貝酸緩釋膠囊是否有專利？如果有，為什么FDA還批準非諾貝酸片？
已經(jīng)有8人回復
- 如何在FDA下載藥品申報材料
已經(jīng)有6人回復
- FDA批準羅氏制藥皮膚癌新藥Zelboraf
已經(jīng)有3人回復
- 如何在FDA查詢某一領域正在進行臨床試驗的藥物？
已經(jīng)有8人回復
- 【轉帖】國產(chǎn)PVP遭遇FDA發(fā)難，過氧化物超標
已經(jīng)有7人回復
- 【轉帖】海普瑞“獨家FDA認證”的解析
已經(jīng)有9人回復
- 求救高人指點，F(xiàn)DA批準上市新藥及世界世界首次上市新藥信息
已經(jīng)有4人回復
從頭開始
榮譽版主 (文壇精英)
gost rider~
-
專家經(jīng)驗: +1 - DRDEPI: 2
- 應助: 66 (初中生)
- 貴賓: 3.308
- 金幣: 350018
- 散金: 60688
- 紅花: 595
- 沙發(fā): 1386
- 帖子: 43542
- 在線: 8442小時
- 蟲號: 812211
- 注冊: 2009-07-20
- 專業(yè): 藥劑學
- 管轄: 新藥研發(fā)
2樓2011-09-29 15:37:19
blueskychina
銅蟲 (初入文壇)
- 應助: 2 (幼兒園)
- 金幣: 179.9
- 紅花: 1
- 帖子: 36
- 在線: 79.7小時
- 蟲號: 292311
- 注冊: 2006-11-04
- 性別: GG
- 專業(yè): 藥物毒理
3樓2011-09-29 22:38:09
古可ぷ
榮譽版主 (文壇精英)
- 應助: 91 (初中生)
- 貴賓: 16.835
- 金幣: 19237.1
- 散金: 40372
- 紅花: 275
- 沙發(fā): 183
- 帖子: 25406
- 在線: 1082.3小時
- 蟲號: 1034379
- 注冊: 2010-06-02
- 性別: GG
- 專業(yè): 藥物設計與藥物信息
- 管轄: 導師招生
4樓2011-09-29 22:47:09
相關版塊跳轉
我要訂閱樓主 古可ぷ 的主題更新
| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 334求調(diào)劑 +3 | 志存高遠意在機?/a> 2026-03-16 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 299求調(diào)劑 +4 | △小透明* 2026-03-17 | 4/200 |
|
|
|
[考研] 290求調(diào)劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
|
[考研] 一志愿蘇州大學材料工程（085601）專碩有科研經(jīng)歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[考研]
 11408 一志愿西電，277分求調(diào)劑
+3
|
zhouzhen654 2026-03-16 | 3/150 |
|
|
|
[考研] 286求調(diào)劑 +3 | lemonzzn 2026-03-16 | 5/250 |
|
|
|
[考研] 一志愿985，本科211，0817化學工程與技術319求調(diào)劑 +5 | Liwangman 2026-03-15 | 5/250 |
|
|
|
[基金申請]
今年的國基金是打分制嗎？
 50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
[考研] 0703化學調(diào)劑，求各位老師收留 +8 | 秋有木北 2026-03-14 | 8/400 |
|
|
|
[考研] 0703 物理化學調(diào)劑 +3 | 我可以上岸的對?/a> 2026-03-13 | 5/250 |
|
|
|
[考研] 本科南京大學一志愿川大藥學327 +3 | 麥田耕者 2026-03-14 | 3/150 |
|
|
|
[基金申請] 現(xiàn)在如何回避去年的某一個專家，不知道名字 +3 | zk200107 2026-03-12 | 6/300 |
|
|
|
[考研] 復試調(diào)劑 +4 | z1z2z3879 2026-03-14 | 5/250 |
|
|
|
[考研] 297求調(diào)劑 +4 | 學海漂泊 2026-03-13 | 4/200 |
|
|
|
[考研] 材料與化工（0856）304求B區(qū)調(diào)劑 +6 | 邱gl 2026-03-12 | 7/350 |
|
|
|
[考研] 290求調(diào)劑 +9 | ADT 2026-03-11 | 9/450 |
|
|
|
[考研] 304求調(diào)劑 +7 | 7712b 2026-03-13 | 7/350 |
|
|
|
[考研] 求b區(qū)學校調(diào)劑 +3 | 周56 2026-03-11 | 3/150 |
|
|
|
[考研] 工科材料085601 279求調(diào)劑 +8 | 困于星晨 2026-03-12 | 10/500 |
|
|
|
[考研] 0817化學工程與技術考研312分調(diào)劑 +3 | T123 tt 2026-03-12 | 3/150 |
|